On November 14, 2024, ZyVersa Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, reported its financial results for the third quarter ended September 30, 2024, and provided a business update. The company announced the upcoming Phase 2a clinical trial for VAR 200 in diabetic kidney disease, expected to begin in Q1-2025, and the formation of a new Scientific Advisory Board to support the development of IC 100 for obesity with metabolic complications. Two proof-of-concept studies for IC 100 are planned, with at least one study commencing in Q4-2024. An IND submission for IC 100 is targeted for Q2-2025, followed by a Phase 1 clinical trial. ZyVersa raised approximately $3.9 million from the beginning of Q3-2024 to the present. The company reported a net loss of $2.4 million for the quarter, a 17.3% improvement compared to the same period in the previous year. Research and development expenses decreased by 35.3%, and general and administrative expenses decreased by 17.7%. ZyVersa will require additional financing to continue operations and meet its milestones, and plans to seek funds through various sources, including equity or debt financings, collaborations, or warrant exercises.

On November 14, 2024, ZyVersa Therapeutics, Inc., a clinical-stage specialty biopharmaceutical company, reported its financial results for the third quarter ended September 30, 2024, and provided a business update. The company announced the upcoming Phase 2a clinical trial for VAR 200 in diabetic kidney disease, expected to begin in Q1-2025, and the formation of a new Scientific Advisory Board to support the development of IC 100 for obesity with metabolic complications. Two proof-of-concept studies for IC 100 are planned, with at least one study commencing in Q4-2024. An IND submission for IC 100 is targeted for Q2-2025, followed by a Phase 1 clinical trial. ZyVersa raised approximately $3.9 million from the beginning of Q3-2024 to the present. The company reported a net loss of $2.4 million for the quarter, a 17.3% improvement compared to the same period in the previous year. Research and development expenses decreased by 35.3%, and general and administrative expenses decreased by 17.7%. ZyVersa will require additional financing to continue operations and meet its milestones, and plans to seek funds through various sources, including equity or debt financings, collaborations, or warrant exercises.